How do we prevent transfusion‐associated graft‐versus‐host disease in children?
2011; Wiley; Volume: 51; Issue: 5 Linguagem: Inglês
10.1111/j.1537-2995.2010.03011.x
ISSN1537-2995
Autores Tópico(s)Blood transfusion and management
ResumoTransfusionVolume 51, Issue 5 p. 916-920 How do we prevent transfusion-associated graft-versus-host disease in children? Karen E. King, Karen E. King From the Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.Search for more papers by this authorPaul M. Ness, Paul M. Ness From the Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.Search for more papers by this author Karen E. King, Karen E. King From the Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.Search for more papers by this authorPaul M. Ness, Paul M. Ness From the Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.Search for more papers by this author First published: 14 January 2011 https://doi.org/10.1111/j.1537-2995.2010.03011.xCitations: 15 Karen E. King, MD, Johns Hopkins Hospital, 550 North Broadway, Suite 810, Baltimore, MD 21205; e-mail: [email protected]. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sanguinis 2008; 95: 85-93. 2 Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol 2009; 21 Suppl 1: S39-41. 3 Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112: 2617-26. 4 Aoun E, Shamseddine A, CheHal A, Obeid M, Taher A. Transfusion-associated GVHD: 10 years' experiences at the American University of Beirut-Medical Center. Transfusion 2003; 43: 1672-6. 5 Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, Lucas G, Beatty C, Casbard A, Cohen H. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus host disease. Transfusion 2007; 47: 1455-67. 6 Agbaht K, Altintas ND, Topeli A, Gokoz O, Ozcebe O. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature. Transfusion 2007; 47: 1405-11. 7 Friedman DF, Kwittken P, Cizman B, Argyris E, Kearns J, Yang SY, Zmijewski C, Bunin N, Douglas SD, Monos D. DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion-associated graft-versus-host disease. Clin Diag Lab Immunol 1994; 1: 590-6. 8 Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion 2002; 42: 1567-72. 9 TH Price, editor. Standards for blood banks and transfusion services. 26th ed. Bethesda (MD): American Association of Blood Banks; 2009. 10 JD Roback, MR Combs, BJ Grossman, CD Hillyer, editors. Technical manual. 16th ed. Bethesda (MD): American Association of Blood Banks; 2008. 11 Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003; 43: 1667-71. 12 Anderson KC, Goodnough LT, Sayers M, Pisciotto PT, Kurtz SR, Lane TA, Anderson CS, Silberstein LE. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991; 77: 2096-101. 13 Weiss B, Hoffmann M, Anders C, Hellstern P, Schmitz N, Uppenkamp M. Gamma-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers. Ann Hematol 2004; 83: 44-9. 14 King KE, Ness PM. Prevention of transfusion-associated graft-versus-host disease in undiagnosed severe combined immunodeficiency syndrome. Blood 1996; 88 Suppl 1: 528a. 15 Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008; 122: 1087-96. 16 Ness PM, Lipton KS. Selective transfusion protocols: errors and accidents waiting to happen. Transfusion 2001; 41: 713-5. 17 Anderson KC. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components. Transfusion 2003; 43: 1652-4. 18 Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996; 10: 31-43. 19 Alyea EP, Anderson KC. Transfusion-associated graft-versus-host disease. In: MA Popovsky, editor. Transfusion reactions. 3rd ed. Bethesda (MD): American Association of Blood Banks; 2007. p. 229-49. 20 Otsubo H, Yamaguchi K. Current risks in blood transfusion in Japan. Jpn J Infect Dis 2008; 61: 427-33. Citing Literature Volume51, Issue5May 2011Pages 916-920 ReferencesRelatedInformation
Referência(s)